Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is a promising clinical-stage biopharmaceutical company that is utilizing precision medicine to develop novel anti-cancer treatments. With its current valuation and a BUY rating, the stock seems attractive for investors, as it has potential for significant upside according to a NPV analysis. This potential upside balances out the inherent risks associated with the company's development stage.

Bears say

Allarity Therapeutics is facing financial challenges such as negative earnings per share and a significant amount of debt. Although the company has developed a personalized drug response technology and is currently conducting clinical trials for its lead drug, Stenoparib, it may struggle to obtain regulatory approvals and gain market traction due to increasing competition in the PARP inhibitors market and changing macroeconomic factors. Furthermore, the company's cash reserves may not be sufficient to support its operations in the long term, creating potential liquidity risks.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.